[{"id":"a9ff4f76-2282-4d1f-9d45-07b786992ee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241834","created_at":"2022-02-16T18:53:36.129Z","updated_at":"2024-07-02T16:35:12.547Z","phase":"Phase 1","brief_title":"A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment","source_id_and_acronym":"NCT05241834","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-27"},{"id":"1cd4bf5f-edfe-4d2a-b079-73a5000d620a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225259","created_at":"2022-02-05T18:29:52.250Z","updated_at":"2024-07-02T16:35:17.299Z","phase":"","brief_title":"Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor","source_id_and_acronym":"NCT05225259","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-28"}]